Craft

VBI Vaccines

Stock Price

$0

2024-10-09

Market Capitalization

$1.9 M

2024-10-09

Revenue

$8.7 M

FY, 2023

VBI Vaccines Summary

Company Summary

Overview
VBI Vaccines, Inc. is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets.
Type
Public
Status
Active
Founded
2001
HQ
Cambridge, MA, US | view all locations
Website
https://www.vbivaccines.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Steven Gillis, Chairman of the Board

    • David E. Anderson

      David E. Anderson, Chief Scientific Officer

    • Blaine McKee
    • Francisco Diaz-Mitoma

      Francisco Diaz-Mitoma, Chief Medical Officer

    LocationsView all

    3 locations detected

    • Cambridge, MA HQ

      United States

      222 Third St #2241cambridge

    • Ottawa, ON

      Canada

      310 Hunt Club Rd #201ottawa

    • Rehovot, Center District

      Israel

      Derech Gad Feinstein

    VBI Vaccines Financials

    Summary Financials

    Revenue (Q1, 2024)
    $1.2M
    Net income (Q1, 2024)
    ($17.9M)
    Cash (Q1, 2024)
    $12.6M
    EBIT (Q1, 2024)
    ($11.8M)
    Enterprise value
    $86.8M

    Footer menu